CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← SELLAS Life Sciences Group, Inc. (SLS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

SELLAS Life Sciences Group, Inc. (SLS)

Pharmaceutical Preparations · market cap $2.3B · as of 2026-11-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-30 (est.)
Phase 2
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
SELLAS Life Sciences (SLS) is a clinical-stage pharmaceutical company with a market cap of about $1.6B (about 204M shares at about $7.86). Its lead asset, Galinpepimut-S, is in Phase 3 for acute myeloid leukemia (AML). The pipeline also includes SLS009 in Phase 2 for hematologic malignancies and a Galinpepimut-S + Montanide + GM-CSF combination in Phase 2 for malignant pleural mesothelioma. The balance sheet shows $134.7M cash, no net debt, and an estimated 68-month runway.
The catalyst path
  • 2026-12-30 (est.)Phase 2 · SLS009imp 7/10
Pipeline
AssetPhaseIndication
Galinpepimut-SPhase 3Acute Myeloid Leukemia
Galinpepimut-S + Montanide + GM-CSFPhase 2Malignant Pleural Mesothelioma
SLS009Phase 2Hematologic Malignancies
Price & technical context
3-month
-39.8%
6-month
+8.1%
12-month
+439.7%
52-wk range
$1.39–$15.46
vs 50-day MA
-27.8%
vs 200-day MA
-10.5%
Realized vol
107.8%
Max drawdown
-49.2%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for SLS (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.